Thymoglobulin: Phase IIa results; marketed to prevent rejection of renal transplants

SANG said that in a Canadian Phase IIa study of 69 patients with hematopoietic malignancies receiving thymoglobulin as an adjunct to standard treatment, transplant-related mortality at 2 years was 6±3...